A Bucci

Sapienza University of Rome, Roma, Latium, Italy

Are you A Bucci?

Claim your profile

Publications (26)31.84 Total impact

  • Source
  • Source
  • Source
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An open-labeled randomized trial with parallel groups was carried out to study the effects of Dif1stat (Monascus purpureus-Linear aliphatic alcohols-Niacin) in the treatment of primary moderate hypercholesterolemia. The trial lasted 8 months. The patients, males and females, were assigned to two groups: A (#130), treated with diet, and B (#110) submitted to diet + Dif1stat. After 4 months, group A did not show significant changes in Total cholesterol (TC), LDL-cholesterol (LDLC), HDL-cholesterol (HDLC) or non-HDL-cholesterol (non-HDLC). The same group, showed a reduction in TC (-22%), LDLC (-30%) and non-HDLC (-27%) after 8 months (P < or = 0.001). After 4 months, TC (-21.3%), LDLC (-29%), and non-HDLC (-26%) were significantly lowered in group B (P < or = 0.001). In group B, TC, LDLC and non-HDLC showed a further reduction after 8 months: -29.4, -38 and -37%, respectively (P < or = 0.001). Even triglycerides (TG) decreased significantly (-33%) (P < or = 0.001). After 8 months, group B showed a significant reduction of TG (-33%) (P < or = 0.001), when compared to group A. Some safety parameters were significantly reduced in both groups: AST and gamma-GT in group A after 4 and 8 months, as well as ALT, AST and gamma-GT in group B after 8 months (P < or = 0.001). Dif1stat, given with a suitable diet, was well tolerated in the long-term and induced an anti-atherogenic plasma lipid and lipoprotein profile, in patients with moderate hypercholesterolemia.
    Lipids 11/2009; 44(12):1141-8. DOI:10.1007/s11745-009-3368-5 · 2.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the favorable effects of reduction of low-density lipoprotein-cholesterol (LDL-C) levels in decreasing the risk of coronary heart disease, many patients treated with lipid-lowering HMG-CoA reductase inhibitors (statins) do not achieve goal LDL-C levels. This may be due to high doses of statins prescribed that could potentially induce adverse effects and compromise patient safety and compliance with considerable expense in the long-term. We compared the actions of rosuvastatin and atorvastatin, administered at the low dosages of 10 and 20 mg/day, respectively, in reducing plasma LDL-C levels and their effects on other components of the atherogenic lipid profile in patients with primary hypercholesterolemia. In this randomized, parallel group, open-label clinical study, 106 patients with LDL-C >200 mg/dL were treated with rosuvastatin 10 mg/day (group A; n = 52), or atorvastatin 20 mg/day (group B; n = 54) for 48 weeks. At 48 weeks, rosuvastatin 10 mg/day was associated with a significantly greater reduction in plasma LDL-C levels compared with atorvastatin 20 mg/day (-44.32% vs -30%; p < 0.005). Compared with atorvastatin, rosuvastatin also produced a greater reduction in plasma total cholesterol, triglycerides, and non-high-density lipoprotein-cholesterol (non-HDL-C) levels (p < 0.005). Plasma HDL-C levels were not affected significantly, independent of the drug used. In high-risk patients with primary hypercholesterolemia, rosuvastatin 10 mg/day was more efficacious than atorvastatin 20 mg/day in reducing plasma LDL-C levels, enabling goal LDL-C levels to be achieved and improving other lipid parameters. Both treatments were well tolerated over 48 weeks.
    American Journal of Cardiovascular Drugs 01/2008; 8(4):265-70. · 2.20 Impact Factor
  • Source
    American Journal of Cardiovascular Drugs 01/2008; 8(4):265-270. DOI:10.2165/00129784-200808040-00006 · 2.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In order to assess the long-term (12 months) efficacy and safety of fenofibrate administered with simvastatin in the treatment of primary mixed hyperlipidaemia, we conducted a study that compared increasing dosages of these drugs in subgroups of men and women belonging to a clinical sample of out-patients. This was an open study carried out in patients with primary mixed hyperlipidaemia (lipoprotein phenotype IIb) who needed a combined therapeutic approach because of their poor response to a single-drug regimen with an HMG-CoA reductase inhibitor (simvastatin). Thus, a fibrate (fenofibrate) was added to the therapy. The study lasted 12 months. Forty-five patients (mean age: 58.9 +/- 11.3 years) with primary mixed hyperlipidaemia who showed a poor response to the single-drug hypolipidaemic treatment were enrolled. Their average plasma triglyceride level was consistently above 300 mg/dL and low-density lipoprotein cholesterol (LDL-C) was over 160 mg/dL after at least 6 months of a single hypolipidaemic drug (simvastatin) regimen plus antiatherogenic dietary treatment. Five patients received simvastatin 10mg once daily in addition to fenofibrate 200mg; 26 patients received simvastatin 20mg once daily plus fenofibrate 200mg; 11 patients received simvastatin 20mg once daily plus fenofibrate 300mg; and three patients received simvastatin 30mg once daily plus fenofibrate 200mg. The patients were allocated to treatment groups on the basis of their relative response to the therapy. Those making up the progressively higher agent/dose groups were the individuals at higher cardiovascular risk according to the total cholesterol and non-high-density lipoprotein cholesterol (HDL-C) values. The double-drug regimen given for 12 months to four different groups, according to the different combined dosages of simvastatin and fenofibrate, resulted in a reduction in total cholesterol of 18% (p </= 0.05) to 39% (p </= 0.05), in LDL-C of 21% (not significant) to 39% (p </= 0.05) and in triglycerides of 35% (p </= 0.05) to 56% (p </= 0.01), and an increase in HDL-C of 8% (p </= 0.05) to 30% (not significant). The cardiovascular risk ratio (total cholesterol/HDL-C) at the end of the study was reduced by 33-60%, whereas the non-HDL-C decreased by 25-38%. No serious adverse effects were reported by the patients. Neither liver biochemistry nor creatine kinase serum concentration were significantly changed. Discontinuation of treatment, if necessary, in case of the occurrence of clinically subjective or objective evidence of adverse effects was assured. The results confirmed the efficacy of the combination of fenofibrate and simvastatin. The combined therapeutic approach was shown to be safe for the treatment of primary mixed hyperlipidaemia, at least in patients with normal hepatic and renal function.
    Clinical Drug Investigation 02/2004; 24(8):465-77. DOI:10.2165/00044011-200424080-00005 · 1.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this short-term open label clinical pilot study, conducted at one center, the immune complex dextran sulphate adsorber (Selesorb) was used to treat four female patients aged 59-69 with HCV-related cryoglobulinaemia, vasculitis and/or neuropathy. The primary trial objective was to assess the clinical efficacy of the immunoadsorber. The secondary objective of the trial was to determine the safety of the adsorber and to investigate the adsorption capacity, measured as the adsorption of cryoglobulin-related immune complexes and the resulting influence on plasma components of the immune system. The patients have been submitted to treatment with the immunoadsorber, at approximately 1-3 days intervals, completing six sessions. The follow-up was one month. In the patients treated with Selesorb, we observed a statistically significant decrease in plasma of all classes of immunoglobulins (IgA: 5-28%; IgG: 14-44%; IgM: 8-38%). In two patients with peripheral neuropathy secondary to cryoglobulinemia, the symptomatology was improved. In a third patient the neurological involvement was substantially unchanged, and the same unsuccessful outcome was observed for Sjögren syndrome is concerned. Nevertheless, the two patients with lower extremity vasculitis showed an appreciable improvement. We failed to observe significant side effects directly related to the use of this immunoadsorbent.
    Transfusion and Apheresis Science 07/2003; 28(3):207-14. DOI:10.1016/S1473-0502(03)00055-7 · 1.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper reports the results of an experimental investigation of fluid flow and single-phase heat transfer of water in stainless steel capillary tubes. Three tube diameters are tested: 172 µm, 290 µm and 520 µm, while the Reynolds number varying from 200 up to 6000. Fluid flow experimental results indicate that in laminar flow regime the friction factor is in good agreement with the Hagen-Poiseuille theory for Reynolds number below 800-1000. For higher values of Reynolds number, experimental data depart from the Hagen-Poiseuille law to the side of higher f values. The transition from laminar to turbulent regime occurs for Reynolds number in the range 1800-3000. This transition is found in good agreement with the well known flow transition for rough commercial tubes. Heat transfer experiments show that heat transfer correlations in laminar and turbulent regimes, developed for conventional size tubes, are not adequate for calculation of heat transfer coefficient in microtubes. In laminar flow the experimental values of heat transfer coefficient are generally higher than those calculated with the classical correlation, while in turbulent flow regime experimental data do not deviate significantly from classical heat transfer correlations. Deviation from classical heat transfer correlations increase as the channel diameter decrease.
    First International Conference on Microchannels and Minichannels, Rochester, New York, USA; 04/2003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper reports the results of an experimental investigation of fluid flow and single-phase heat transfer of water in stainless steel capillary tubes. Three tube diameters are tested: 172 µm, 290 µm and 520 µm, while the Reynolds number varying from 200 up to 6000. Fluid flow experimental results indicate that in laminar flow regime the friction factor is in good agreement with the Hagen-Poiseuille theory for Reynolds number below 800-1000. For higher values of Reynolds number, experimental data depart from the Hagen-Poiseuille law to the side of higher f values. The transition from laminar to turbulent regime occurs for Reynolds number in the range 1800-3000. This transition is found in good agreement with the well known flow transition for rough commercial tubes. Heat transfer experiments show that heat transfer correlations in laminar and turbulent regimes, developed for conventional size tubes, are not adequate for calculation of heat transfer coefficient in microtubes. In laminar flow the experimental values of heat transfer coefficient are generally higher than those calculated with the classical correlation, while in turbulent flow regime experimental data do not deviate significantly from classical heat transfer correlations. Deviation from classical heat transfer correlations increase as the channel diameter decrease.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to assess the effects of the dietary intake of extra virgin olive oil on the oxidative susceptibility of low density lipoproteins (LDL) isolated from the plasma of hyperlipidemic patients. Ten patients with combined hyperlipidemia (mean plasma cholesterol 281 mg/dL, triglycerides 283 mg/dL) consumed a low-fat, low-cholesterol diet, with olive oil (20 g/d) as the only added fat, with no drug or vitamin supplementation for 6 wk. Then they were asked to replace the olive oil they usually consumed with extra virgin olive oil for 4 wk. LDL were isolated at the beginning, and after the 4 wk of dietary treatment. LDL susceptibility to CuSO4-mediated oxidation was evaluated by measuring the extent of lipid peroxidation. We also determined fatty acid composition and vitamin E in plasma and LDL and plasma phenolic content. Extra virgin olive oil intake did not affect fatty acid composition of LDL but significantly reduced the copper-induced formation of LDL hydroperoxides and lipoperoxidation end products as well as the depletion of LDL linoleic and arachidonic acid. A significant increase in the lag phase of conjugated diene formation was observed after dietary treatment. These differences are statistically correlated with the increase in plasma phenolic content observed at the end of the treatment with extra virgin olive oil; they are not correlated with LDL fatty acid composition or vitamin E content, which both remained unmodified after the added fat change. This report suggests that the daily intake of extra virgin olive oil in hyperlipidemic patients could reduce the susceptibility of LDL to oxidation, not only because of its high monounsaturated fatty acid content but probably also because of the antioxidative activity of its phenolic compounds.
    Lipids 12/2001; 36(11):1195-202. DOI:10.1007/s11745-001-0832-3 · 2.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of the present study was to assess the effect of consumption of a yoghurt-based drink enriched with 1-2 g plant sterols/d on serum lipids, transaminases, vitamins and hormone status in patients with primary moderate hypercholesterolaemia. Thirty patients were randomly assigned to one of two treatment groups: a low-fat low-lactose yoghurt-based drink enriched with 1 g plant sterol extracted from soyabean/d v. a low-fat low-lactose yoghurt, for a period of 4 weeks. After a 2-week wash-out period, patients were crossed over for an additional 4-week period. Second, after a 4-week wash-out period, eleven patients were treated with 2 g plant sterols/d in a second open part of the study for a period of 8 weeks. The yoghurt enriched with plant sterols significantly reduced, in a dose-dependent manner, serum total cholesterol and LDL-cholesterol levels and LDL-cholesterol:HDL-cholesterol (P<0.001), whereas no changes were observed in HDL-cholesterol and triacylglycerol levels, either in the first or the second part of the study. There were only slight, not statistically significant, differences in serum transaminase, vitamin and hormone levels. To conclude, a low-fat yoghurt-based drink moderately enriched with plant sterols may lower total cholesterol and LDL-cholesterol effectively in patients with primary moderate hypercholesterolaemia.
    British Journal Of Nutrition 09/2001; 86(2):233-9. DOI:10.1079/BJN2001395 · 3.34 Impact Factor
  • Source
    Atherosclerosis 10/1997; 134(1):383-383. DOI:10.1016/S0021-9150(97)89937-6 · 3.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The association of serum selenium (S-Se) with selected cardiovascular risk factors has been studied in 3404 (1520 men, 1884 women) of 4699 subjects aged 20-73 years, who underwent a comprehensive examination between April 1986 and December 1987 within the framework of the Di.S.Co. Research Project of the National Research Council. Mean S-Se concentrations were 1.163 (SD 0.170) μmol/liter, 1.156 (0.163) μmol/liter, and 1.171 (0.179) μmol/liter in the total group, and female and male subjects, respectively. The difference by sex was statistically significant (F = 6.97, P = 0.0083). In male subjects S-Se levels were inversely associated to age (simple correlation coefficient, r = −0.2135, P < 0.001), alcohol consumption (Alcohol, r = −0.0688, P < 0.01), smoking habit (Smoke, r = −0.0663, P < 0.01), body mass index (BMI, r = −0.0596, P < 0.02), and lognormal transformation of triglycerides (Ln-Trig, r = −0.0767, P < 0.005). In multiple regression analysis Age, Smoke, Ln-Trig, and Alcohol remained significantly and inversely related to S-Se; a significant direct association of S-Se to high-density lipoprotein cholesterol (HDL) and non-HDL cholesterol (non-HDL) was also pointed out. In female subjects, S-Se was directly related to HDL (r = 0.1436, P < 0.001) and non-HDL (r = 0.0967, P < 0.001). In multiple regression analysis S-Se was directly related to both HDL and non-HDL and an inverse significant association of S-Se to Age and Alcohol was evidenced. In multivariate regression models analyzing systolic (SEP), diastolic (DBP), and mean blood pressure (MBP) as dependent variables, S-Se was a weak significant positive predictor in male but not in female subjects.
    Microchemical Journal 02/1995; 51(s 1–2):170–180. DOI:10.1006/mchj.1995.1022 · 3.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ability of glycosaminoglycans to bind to a wide number of biologically active macromolecules has already been investigated. Recent clinical trials on the possible therapeutic benefits of glycosaminoglycans must be placed in perspective, even if they appear to be particularly encouraging, especially as regards the glycosaminoglycan effects on certain coagulation factors. A multicenter, medium-term, double-blind, crossover trial was performed by several Italian Lipid Clinics to determine whether administration of a medium molecular weight glycosaminoglycan (Sulodexide) has a significant clinical effect. Patients affected by peripheral vascular disease and/or hyperlipidemia (type IIa, IIb and IV) were submitted to a 4-week wash-out period, followed by parenteral Sulodexide (S) or placebo (P) administration for 2 weeks, another 2 week wash-out period, parenteral crossover drug or P administration for 2 weeks and, finally, oral S administration for 6 months. Sulodexide lowered plasma viscosity and plasma fibrinogen in all patients. There was also a drop in triglycerides together with a rise in apo A-I and HDL-C in type IV hyperlipoproteinemics, whereas there was no significant effect on total or LDL-plasma cholesterol in type IIa and IIb patients. Moreover, there was a percent increase in peak flow and rest flow in the lower limbs of peripheral vascular disease patients. No side effects or intolerance phenomena were detected. The results indicate that Sulodexide administration may be useful in long-term treatment of patients with peripheral vascular disease and a concomitant increase in plasma triglycerides and/or fibrinogen and/or viscosity.
    Atherosclerosis 04/1990; 81(3):233–243. DOI:10.1016/0021-9150(90)90071-P · 3.97 Impact Factor
  • Source
    Beiträge zur Infusionstherapie = Contributions to infusion therapy 02/1988; 23:172-82.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The relation between arterial blood pressure and erythrocyte fatty acid composition was investigated in a large urban female population aged 20-69 years. No significant differences in the relative amounts of saturated, monounsaturated and polyunsaturated (n-6 and n-3 series) fatty acids and in the mean polyunsaturated/saturated and linoleic/oleic ratios were observed in the different quartiles of both systolic and diastolic blood pressure. Moreover, there was no significant correlation between individual erythrocyte fatty acids and their ratios and either blood pressure or other risk factors for atherosclerosis (age, body mass index, total serum cholesterol and triglycerides). In the multivariate analysis no independent correlations between systolic and diastolic blood pressure and the individual erythrocyte fatty acids were observed; age and body mass index were strongly related to blood pressure. Our results do not confirm for erythrocyte fatty acids the reported associations between plasma fatty acids and blood pressure.
    Scandinavian Journal of Clinical and Laboratory Investigation 05/1987; 47(2):105-10. DOI:10.1080/00365518709168877 · 2.01 Impact Factor
  • Monographs on atherosclerosis 02/1986; 14:83-90.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Not available. Language: English
    Atherosclerosis and Cardiovascular Diseases, Edited by Lenzi S. and Descovich G.C., 01/1986: chapter B-mode echography: a new approach to the Epidemiology of Atherosclerotic Disease?: pages 529-534; MTP Press Limited, Lancaster, Boston.